Literature DB >> 19201847

Naive mouse macrophages become activated following recognition of L5178Y lymphoma cells via concurrent ligation of CD40, NKG2D, and CD18 molecules.

Ilia N Buhtoiarov1, Alexander L Rakhmilevich, Lewis L Lanier, Erik A Ranheim, Paul M Sondel.   

Abstract

Under different circumstances, tumors can inhibit or activate macrophage (Mphi) effector functions. We studied the mechanisms of tumor-Mphi interactions leading to Mphi activation. The results show that L5178Y mouse T cell lymphoma cells can prime naive mouse Mphi to subsequent LPS stimulation, resulting in increased NO production and antilymphoma effects in vitro. L5178Y cells, but not naive splenocytes, primed Mphi to ligation of TLR4 but not TLR9. L5178Y-primed Mphi incubated with LPS showed down-regulation of CD40 and up-regulation of NKG2D expression. Although L5178Y T cell lymphoma cells primed naive mouse Mphi, several other mouse and human cells lines failed to prime mouse Mphi. Neither L5178Y-conditioned supernatants nor coculture of Mphi and L5178Y cells in Transwells resulted in priming, indicating that direct L5178Y cell-Mphi contact was needed. Several receptor-ligand pairs are reciprocally expressed on Mphi and L5178Y cell membranes and can be potentially involved in Mphi priming. Of these, the CD40-CD154 pair played the most important role, as blocking the interaction of these molecules substantially reduced in vitro Mphi priming. Furthermore, simultaneous blocking of interactions between CD40-CD154, NKG2D-H60, and CD18-ICAM-1/2 led to complete abrogation of Mphi-mediated NO secretion and complete inhibition of Mphi-mediated tumor cell cytostasis. The priming of Mphi to LPS with L5178Y cells was also observed in vivo. These results suggest that contact with certain tumor cells via CD40, NKG2D, and CD18 molecules on the Mphi may facilitate Mphi-mediated antitumor immune surveillance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19201847      PMCID: PMC2757113          DOI: 10.4049/jimmunol.0800443

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity.

Authors:  N S Liao; M Bix; M Zijlstra; R Jaenisch; D Raulet
Journal:  Science       Date:  1991-07-12       Impact factor: 47.728

2.  Maintenance and cure of the L5178Y murine tumor-dormant state by interleukin 2: dependence of interleukin 2 on induced interferon-gamma and on tumor necrosis factor for its antitumor effects.

Authors:  L P Chen; Y Suzuki; C M Liu; E F Wheelock
Journal:  Cancer Res       Date:  1990-03-01       Impact factor: 12.701

3.  Mechanisms of tumor cell capture by activated macrophages: evidence for involvement of lymphocyte function-associated (LFA)-1 antigen.

Authors:  G Strassmann; T A Springer; S D Somers; D O Adams
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

4.  MHC class-I antigen deficiency, malignancy and susceptibility of P815 mastocytoma to NK and macrophage killing.

Authors:  M Bertschmann; D Käsermann; R Keller
Journal:  Int J Cancer       Date:  1990-10-15       Impact factor: 7.396

5.  Interferon-gamma inhibits the proliferation but not the differentiation of murine B cells in response to IL-5.

Authors:  Y Hitoshi; S Mita; A Tominaga; Y Kikuchi; E Sonoda; K Takatsu; Y Watanabe
Journal:  Int Immunol       Date:  1989       Impact factor: 4.823

6.  Establishment and control of the L5178Y-cell tumor dormant state in DBA/2 mice.

Authors:  E F Wheelock; M K Robinson; G A Truitt
Journal:  Cancer Metastasis Rev       Date:  1982       Impact factor: 9.264

7.  The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas/leukemias.

Authors:  A Carbone; A Gloghini; V Zagonel; D Aldinucci; V Gattei; M Degan; S Improta; R Sorio; S Monfardini; A Pinto
Journal:  Blood       Date:  1995-12-15       Impact factor: 22.113

8.  Phenotypic and functional characterization of T-BAM (CD40 ligand)+ T-cell non-Hodgkin's lymphoma.

Authors:  G Inghirami; S Lederman; M J Yellin; A Chadburn; L Chess; D M Knowles
Journal:  Blood       Date:  1994-08-01       Impact factor: 22.113

9.  Maintenance and cure of the L5178Y murine tumor-dormant state by interleukin 2: in vivo and in vitro effects.

Authors:  C M Liu; Y Suzuki; L P Chen; T Okayasu; C E Calkins; E F Wheelock
Journal:  Cancer Res       Date:  1990-03-01       Impact factor: 12.701

10.  Characterization and purification of a macrophage-triggering factor produced in Mycoplasma arginini-infected L5178Y cell cultures.

Authors:  G Yang; F D Coffman; E F Wheelock
Journal:  J Immunol       Date:  1994-09-15       Impact factor: 5.422

View more
  6 in total

1.  Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.

Authors:  Ilia N Buhtoiarov; Paul M Sondel; Jon M Wigginton; Tatiana N Buhtoiarova; Eric M Yanke; David A Mahvi; Alexander L Rakhmilevich
Journal:  Immunology       Date:  2010-10-13       Impact factor: 7.397

Review 2.  NKG2D Receptor and Its Ligands in Host Defense.

Authors:  Lewis L Lanier
Journal:  Cancer Immunol Res       Date:  2015-06       Impact factor: 11.151

Review 3.  Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Authors:  Fotis Asimakopoulos; Jaehyup Kim; Ryan A Denu; Chelsea Hope; Jeffrey L Jensen; Samuel J Ollar; Ellen Hebron; Claire Flanagan; Natalie Callander; Peiman Hematti
Journal:  Leuk Lymphoma       Date:  2013-04-11

4.  Cutting edge: FcR-like 5 on innate B cells is targeted by a poxvirus MHC class I-like immunoevasin.

Authors:  Jessica A Campbell; Randall S Davis; Lauren M Lilly; Daved H Fremont; Anthony R French; Leonidas N Carayannopoulos
Journal:  J Immunol       Date:  2010-06-02       Impact factor: 5.422

5.  Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG.

Authors:  Kory L Alderson; Mitchell Luangrath; Megan M Elsenheimer; Stephen D Gillies; Fariba Navid; Alexander L Rakhmilevich; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2012-11-15       Impact factor: 6.968

Review 6.  The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease.

Authors:  Ana Stojanovic; Margareta P Correia; Adelheid Cerwenka
Journal:  Front Immunol       Date:  2018-04-23       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.